Zhejiang Funuo Pharmaceutical

Zhejiang Funuo Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the development of innovative small molecule drugs for oncology. The company's research strategy focuses on targeting key signaling pathways involved in cancer cell proliferation and survival. Its lead clinical candidate, FN-1501, is a potent multi-kinase inhibitor targeting FLT3 and CDK4/6, currently undergoing evaluation in Phase 1/2 trials for acute myeloid leukemia and various solid tumors. Beyond its lead program, Funuo is advancing a diverse pipeline of early-stage assets aimed at addressing drug resistance in cancer therapy. The company maintains a strong R&D presence in China and has expanded its clinical development footprint to include international sites.